Published in Soc Sci Med on May 01, 2002
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med (2006) 8.57
Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav (2006) 8.11
Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr (2009) 3.88
Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc (2013) 3.00
Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr (2006) 2.78
Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med (2004) 2.37
Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health (2008) 2.19
Adherence to antiretroviral therapy: merging the clinical and social course of AIDS. PLoS Med (2005) 1.77
Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med (2014) 1.69
Stressful life events and adherence in HIV. AIDS Patient Care STDS (2008) 1.51
Financial barriers to HIV treatment in Yaoundé, Cameroon: first results of a national cross-sectional survey. Bull World Health Organ (2009) 1.42
Sero-positive African Americans' beliefs about alcohol and their impact on anti-retroviral adherence. AIDS Behav (2007) 1.42
Health literacy, antiretroviral adherence, and HIV-RNA suppression: a longitudinal perspective. J Gen Intern Med (2006) 1.41
The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS Behav (2012) 1.28
Anxiety and depression symptoms as risk factors for non-adherence to antiretroviral therapy in Brazil. AIDS Behav (2008) 1.26
Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the Nutrition for Healthy Living study. J Acquir Immune Defic Syndr (2010) 1.24
Understanding the facilitators and barriers of antiretroviral adherence in Peru: a qualitative study. BMC Public Health (2010) 1.24
Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep (2014) 1.23
Prevalence of childhood sexual abuse and physical trauma in an HIV-positive sample from the deep south. Am J Public Health (2006) 1.22
Antiretroviral adherence during pregnancy and postpartum in Latin America. AIDS Patient Care STDS (2012) 1.20
Heavy alcohol consumption in individuals with HIV infection: effects on neuropsychological performance. J Int Neuropsychol Soc (2005) 1.17
A Social Problem-Solving Model of Adherence to HIV Medications. Health Psychol (2006) 1.15
HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care (2009) 1.14
Patient-clinician relationships and treatment system effects on HIV medication adherence. AIDS Behav (2005) 1.14
Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival. J Womens Health (Larchmt) (2011) 1.07
HIV stigma and depressive symptoms are related to adherence and virological response to antiretroviral treatment among immigrant and indigenous HIV infected patients. AIDS Behav (2012) 1.01
Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients. Eur J Hum Genet (2005) 1.00
Prevalence and predictors of major depression in HIV-infected patients on antiretroviral therapy in Bamenda, a semi-urban center in Cameroon. PLoS One (2012) 0.99
Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. Eur J Clin Pharmacol (2007) 0.98
Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV. AIDS Res Treat (2012) 0.94
Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. Br J Clin Pharmacol (2005) 0.92
Adherence to antiretroviral drug therapy in adult patients who are HIV-positive in Northwest Ethiopia: a study protocol. BMJ Open (2013) 0.91
Cultural rationales guiding medication adherence among African American with HIV/AIDS. AIDS Patient Care STDS (2011) 0.90
Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: A Systematic Review. Am J Public Health (2015) 0.90
Psychiatric symptoms and antiretroviral nonadherence in US youth with perinatal HIV: a longitudinal study. AIDS (2015) 0.88
Trauma, dissociation, and antiretroviral adherence among persons living with HIV/AIDS. J Psychiatr Res (2011) 0.87
Sticking to it: the effect of maximally assisted therapy on antiretroviral treatment adherence among individuals living with HIV who are unstably housed. AIDS Behav (2011) 0.87
Antiretroviral Treatment Adherence Rate and Associated Factors among People Living with HIV in Dubti Hospital, Afar Regional State, East Ethiopia. Int Sch Res Notices (2015) 0.87
Highly stressed: stressful and traumatic experiences among individuals with HIV/AIDS in the Deep South. AIDS Care (2011) 0.86
Antiretroviral treatment and quality of life in Africans living with HIV: 12-month follow-up in Burkina Faso. J Int AIDS Soc (2013) 0.85
Development of a nursing intervention to facilitate optimal antiretroviral-treatment taking among people living with HIV. BMC Health Serv Res (2009) 0.85
In-home mental health treatment for individuals with HIV. AIDS Patient Care STDS (2012) 0.85
Correlates of unstructured antiretroviral treatment interruption in a cohort of HIV-positive individuals in British Columbia. AIDS Behav (2014) 0.83
The relationship of CSF and plasma cytokine levels in HIV infected patients with neurocognitive impairment. Biomed Res Int (2015) 0.82
Rates of initial virological suppression and subsequent virological failure after initiating highly active antiretroviral therapy: the impact of aboriginal ethnicity and injection drug use. Curr HIV Res (2010) 0.79
Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy. BMJ Open (2012) 0.79
Psychosocial burdens negatively impact HIV antiretroviral adherence in gay, bisexual, and other men who have sex with men aged 50 and older. AIDS Care (2014) 0.78
Housing characteristics and their influence on health-related quality of life in persons living with HIV in Ontario, Canada: results from the positive spaces, healthy places study. AIDS Behav (2012) 0.78
Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART). Eur J Clin Microbiol Infect Dis (2011) 0.77
Progress and compliance in alcohol abuse treatment. J Health Econ (2009) 0.77
The Clarification of Depression and Social Support's Contribution to the Prediction of Antiretroviral Medication Adherence and the Rate of CD4 in People with HIV. Glob J Health Sci (2016) 0.75
Counselling Psychology in South Africa. Couns Psychol Q (2016) 0.75
[Factors associated with non-adherence of adults infected with HIV on antiretroviral therapy in a referral hospital in Douala]. Pan Afr Med J (2015) 0.75
HIV/AIDS Competent Households: Interaction between a Health-Enabling Environment and Community-Based Treatment Adherence Support for People Living with HIV/AIDS in South Africa. PLoS One (2016) 0.75
Virus against virus (VIVI): a potential solution against HIV/AIDS. Int Arch Med (2014) 0.75
Illness Representations of HIV Positive Patients Are Associated with Virologic Success. Front Psychol (2016) 0.75
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
An assessment of interactions between global health initiatives and country health systems. Lancet (2009) 10.53
Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA (2002) 4.48
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis (2004) 2.56
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis (2003) 2.54
Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect Dis (2013) 2.51
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS (2002) 2.21
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med (2007) 2.03
Low acceptability of A/H1N1 pandemic vaccination in French adult population: did public health policy fuel public dissonance? PLoS One (2010) 1.98
Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis (2002) 1.90
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
Bivariate linear mixed models using SAS proc MIXED. Comput Methods Programs Biomed (2002) 1.87
Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. Antivir Ther (2013) 1.68
Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS (2010) 1.57
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis (2002) 1.57
General practitioners' attitudes towards patients with disabilities: the need for training and support. Disabil Rehabil (2005) 1.55
Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther (2003) 1.55
De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Med (2014) 1.53
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS (2009) 1.46
Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.44
Diabetes mellitus and infective endocarditis: the insulin factor in patient morbidity and mortality. Eur Heart J (2006) 1.43
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity. AIDS (2008) 1.42
Financial barriers to HIV treatment in Yaoundé, Cameroon: first results of a national cross-sectional survey. Bull World Health Organ (2009) 1.42
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA (2004) 1.42
Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr (2002) 1.41
Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther (2005) 1.40
Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother (2009) 1.39
Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials (2003) 1.36
Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS (2012) 1.36
'Time is costly': modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa. AIDS (2008) 1.35
Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr (2006) 1.35
Decentralization of HIV care in Cameroon: increased access to antiretroviral treatment and associated persistent barriers. Health Policy (2009) 1.31
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill (2015) 1.29
Recommendations for the management of patients after heart valve surgery. Eur Heart J (2005) 1.29
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J Acquir Immune Defic Syndr (2005) 1.29
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS (2004) 1.28
Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS (2007) 1.28
Discrimination against HIV-infected people and the spread of HIV: some evidence from France. PLoS One (2007) 1.27
Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study. Ann Intern Med (2010) 1.27
Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12-116). Trop Med Int Health (2008) 1.26
Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet (2002) 1.26
Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr (2009) 1.25
Positive attitudes of French general practitioners towards A/H1N1 influenza-pandemic vaccination: a missed opportunity to increase vaccination uptakes in the general public? Vaccine (2010) 1.24
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med (2010) 1.24
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis (2009) 1.23
The health-care system: an assessment and reform agenda. Lancet (2009) 1.19
Health related quality of life among both current and former injection drug users who are HIV-infected. Drug Alcohol Depend (2006) 1.18
Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis (2005) 1.18
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother (2009) 1.17
Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination. AIDS (2007) 1.16
European bat Lyssavirus transmission among cats, Europe. Emerg Infect Dis (2009) 1.15
Cerebral microbleeds are frequent in infective endocarditis: a case-control study. Stroke (2009) 1.13
Performance of HIV care decentralization from the patient's perspective: health-related quality of life and perceived quality of services in Cameroon. Health Policy Plan (2011) 1.12
Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study. Antivir Ther (2008) 1.06
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother (2004) 1.05
Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. PLoS One (2011) 1.05
Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematol Oncol (2013) 1.04
Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr (2005) 1.04
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Eur J Clin Pharmacol (2006) 1.04
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis (2011) 1.04
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin Infect Dis (2004) 1.03
Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol (2005) 1.03
Measuring and decomposing socioeconomic inequality in healthcare delivery: A microsimulation approach with application to the Palestinian conflict-affected fragile setting. Soc Sci Med (2010) 1.02
Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. Clin Infect Dis (2012) 1.02
When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience. Antivir Ther (2008) 1.00
Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients. Eur J Hum Genet (2005) 1.00
Prophylaxis of infective endocarditis: current tendencies, continuing controversies. Lancet Infect Dis (2008) 1.00
Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. J Acquir Immune Defic Syndr (2009) 1.00
The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice. Antivir Ther (2007) 0.98
Delayed first consultation after diagnosis of HIV infection in Cameroon. AIDS (2009) 0.98
Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). Int J Drug Policy (2007) 0.98
Impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing. Int J Technol Assess Health Care (2003) 0.98
Behavioural research in epidemics. Lancet Infect Dis (2013) 0.97
Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis (2002) 0.97
Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth? PLoS One (2011) 0.97